Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Ipca Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹1,584.80
High
₹1,654.70
Price Summary
| Previous Close | ₹1,600.70 |
|---|---|
| Day's Range | ₹1,584.80 - ₹1,654.70 |
| Open | ₹1,592.70 |
| 52 Week Range | ₹1,251.60 - ₹1,624.00 |
| Volume | 9,50,097 |
| Market Cap | ₹0.04 |
| Previous Close | ₹1,600.60 |
|---|---|
| Day's Range | ₹1,584.80 - ₹1,654.00 |
| Open | ₹1,603.35 |
| 52 Week Range | ₹1,252.95 - ₹1,624.00 |
| Volume | 40,252 |
| Market Cap | ₹0.04 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 15,208.20 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.25 |
| Price/Earning (TTM) | 44.13 |
| TTM EPS (₹) | 35.86 |
| P/E Ratio | 51.63 |
| Book Value(₹) | 5.15 |
| PAT Margin (%) | 8.81 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 15.27 |
| Trade Value ( ₹ in Lacs) | 644.27 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.25 |
| Price/Earning (TTM) | 44.13 |
| TTM EPS (₹) | 35.86 |
| P/E Ratio | 51.63 |
| Book Value(₹) | 5.15 |
| PAT Margin (%) | 8.81 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 15.27 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 22453.7 | 77050.4 |
| Expenses | N/A | N/A |
| PBT | 3669.5 | 8363.8 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2763.6 | 5229.2 |
About Ipca Laboratories Ltd.
| Founded | 1949 |
|---|---|
| Managing Director | Pranay Godha |
| NSE Symbol | IPCALAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,47,032.09 | 1,880.70 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,83,758.68 | 6,787.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,223.98 | 4,416.45 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,692.75 | 8,075.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,214.23 | 1,434.90 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,08,739.11 | 1,325.00 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,230.20 | 2,277.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,02,166.27 | 1,056.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,01,634.21 | 2,506.95 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 99,747.98 | 1,012.85 | 835.50 - 835.50 |
No Records Found
Latest News
Ipca Laboratories informs about trading window closure
Ipca Laboratories informs about closure of trading window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, Ipca Laboratories has informed that the trading window for dealing in the securities of the Company by the insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st April, 2026 and until 48 hours after the declaration of the Company’s audited financial results for the 4th quarter and financial year ended 31st March, 2026. The date of the Board meeting for consideration of the said audited financial results would be intimated to the stock exchanges in due course of time.
The above information is a part of company’s filings submitted to BSE.
Global Health - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 9606.29 | 8028.68 | 19.65 | 37093.78 | 32041.46 | 15.77 | 37093.78 | 32041.46 | 15.77 |
| Other Income | 358.05 | 256.66 | 39.50 | 1064.08 | 908.09 | 17.18 | 1064.08 | 908.09 | 17.18 |
| PBIDT | 2291.47 | 2208.62 | 3.75 | 8612.69 | 8559.45 | 0.62 | 8612.69 | 8559.45 | 0.62 |
| Interest | 134.64 | 70.99 | 89.66 | 410.85 | 333.91 | 23.04 | 410.85 | 333.91 | 23.04 |
| PBDT | 2156.83 | 1638.67 | 31.62 | 8205.61 | 7726.58 | 6.20 | 8205.61 | 7726.58 | 6.20 |
| Depreciation | 522.08 | 379.80 | 37.46 | 1709.07 | 1496.11 | 14.23 | 1709.07 | 1496.11 | 14.23 |
| PBT | 1634.75 | 1258.87 | 29.86 | 6496.54 | 6230.47 | 4.27 | 6496.54 | 6230.47 | 4.27 |
| TAX | 393.44 | 324.75 | 21.15 | 1534.53 | 1615.19 | -4.99 | 1534.53 | 1615.19 | -4.99 |
| Deferred Tax | 74.98 | -43.90 | -270.80 | 222.11 | -0.34 | -65426.47 | 222.11 | -0.34 | -65426.47 |
| PAT | 1241.31 | 934.12 | 32.89 | 4962.01 | 4615.28 | 7.51 | 4962.01 | 4615.28 | 7.51 |
| Equity | 537.38 | 537.17 | 0.04 | 537.38 | 537.17 | 0.04 | 537.38 | 537.17 | 0.04 |
| PBIDTM(%) | 23.85 | 27.51 | -13.29 | 23.22 | 26.71 | -13.08 | 23.22 | 26.71 | -13.08 |
Senores Pharmaceutic - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 368.10 | 118.60 | 210.37 | 1060.90 | 385.40 | 175.27 | 1060.90 | 385.40 | 175.27 |
| Other Income | 221.90 | 92.50 | 139.89 | 663.50 | 219.90 | 201.73 | 663.50 | 219.90 | 201.73 |
| PBIDT | 187.10 | 65.20 | 186.96 | 476.70 | 147.10 | 224.07 | 476.70 | 147.10 | 224.07 |
| Interest | 18.90 | 23.50 | -19.57 | 69.80 | 65.20 | 7.06 | 69.80 | 65.20 | 7.06 |
| PBDT | 168.20 | 41.70 | 303.36 | 406.90 | 81.90 | 396.83 | 406.90 | 81.90 | 396.83 |
| Depreciation | 41.30 | 12.70 | 225.20 | 132.30 | 30.80 | 329.55 | 132.30 | 30.80 | 329.55 |
| PBT | 126.90 | 29.00 | 337.59 | 274.60 | 51.10 | 437.38 | 274.60 | 51.10 | 437.38 |
| TAX | 42.10 | 8.80 | 378.41 | 72.10 | 14.20 | 407.75 | 72.10 | 14.20 | 407.75 |
| Deferred Tax | -22.70 | 4.00 | -667.50 | -12.40 | -0.30 | 4033.33 | -12.40 | -0.30 | 4033.33 |
| PAT | 84.80 | 20.20 | 319.80 | 202.50 | 36.90 | 448.78 | 202.50 | 36.90 | 448.78 |
| Equity | 460.50 | 460.50 | 0.00 | 460.50 | 460.50 | 0.00 | 460.50 | 460.50 | 0.00 |
| PBIDTM(%) | 50.83 | 54.97 | -7.54 | 44.93 | 38.17 | 17.73 | 44.93 | 38.17 | 17.73 |
Akums Drugs & Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 3383.72 | 3287.53 | 2.93 | 13487.36 | 13117.84 | 2.82 | 13487.36 | 13117.84 | 2.82 |
| Other Income | 277.29 | 320.50 | -13.48 | 1129.65 | 1241.92 | -9.04 | 1129.65 | 1241.92 | -9.04 |
| PBIDT | 395.16 | 497.74 | -20.61 | 2104.25 | 2626.91 | -19.90 | 2104.25 | 2626.91 | -19.90 |
| Interest | 25.93 | 26.26 | -1.26 | 100.38 | 153.09 | -34.43 | 100.38 | 153.09 | -34.43 |
| PBDT | 342.12 | 471.48 | -27.44 | 1938.68 | 2473.82 | -21.63 | 1938.68 | 2473.82 | -21.63 |
| Depreciation | 124.21 | 100.93 | 23.07 | 455.03 | 395.45 | 15.07 | 455.03 | 395.45 | 15.07 |
| PBT | 217.91 | 370.55 | -41.19 | 1483.65 | 2078.37 | -28.61 | 1483.65 | 2078.37 | -28.61 |
| TAX | 65.94 | 94.66 | -30.34 | 367.25 | 468.39 | -21.59 | 367.25 | 468.39 | -21.59 |
| Deferred Tax | 33.28 | 12.05 | 176.18 | -3.69 | -7.14 | -48.32 | -3.69 | -7.14 | -48.32 |
| PAT | 151.97 | 275.89 | -44.92 | 1116.40 | 1609.98 | -30.66 | 1116.40 | 1609.98 | -30.66 |
| Equity | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 |
| PBIDTM(%) | 11.68 | 15.14 | -22.87 | 15.60 | 20.03 | -22.09 | 15.60 | 20.03 | -22.09 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Ipca Laboratories Ltd. is ₹1,600.70 as of 2026-05-15.
The market capitalisation of Ipca Laboratories Ltd. is ₹40,152.50 as of 2026-05-14.
The 1-year return of Ipca Laboratories Ltd. is 16.80% as of 2026-05-15.
The P/E ratio of Ipca Laboratories Ltd. is 51.63 as of 2026-05-15.
The 52-week high and low of Ipca Laboratories Ltd. are ₹1,624.00 and ₹1,251.60, respectively, as of 2026-05-15.
People Also Ask
Ipca Laboratories Ltd. manufactures a vast array of active pharmaceutical ingredients (APIs) and finished drug formulations. The company holds dominant global market shares in producing anti-malarial, rheumatology, and cardiovascular medications, serving both domestic retail and heavy international export markets.
Ipca Laboratories Ltd. works with global entities by exporting heavily vertically integrated APIs and formulations to over 100 countries. It partners with domestic hospitals and clinics through a massive medical representative network that ensures widespread availability of its specialised generic drugs.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
